» Articles » PMID: 10843728

Autocrine and Paracrine Regulation by Cytokines and Growth Factors in Melanoma

Overview
Journal Cytokine
Date 2000 Jun 14
PMID 10843728
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Tumour development and progression involves the expression of oncogenes and inactivation of tumour suppressor genes, leading to the appearance of multiple malignant characteristics. Malignant melanoma cells express different growth factors and cytokines and their receptors in respective stages of tumour progression, which by autocrine and paracrine effects enable them to grow autonomously and confer competence to metastasis. Autocrine growth factors (bFGF, MGSA/GRO, IL-8 and sometimes IL-6, PDGF-A, IL-10) produced by melanoma cells stimulate proliferation of the producing cell itself, while paracrine growth factors (for example PDGF, EGF, TGF-beta, IL-1, GM-CSF, IGF-I, NGF, VEGF) modulate the microenvironment to the benefit of tumour growth and invasion. Paracrine effects include angiogenesis, stroma formation, modulation of host immune response, activation of proteolytic enzymes, adhesion or motility and metastasis formation. Some growth factors have inhibitory effects on melanocytes and early lesions (IL-1, IL-6, TGF-beta, OSM, TNF and IFN) but not on advanced stage melanomas, and in some cases they switch to autocrine stimulator (IL-6, TGF-beta). Understanding the involvement of different growth factors and cytokines in the molecular mechanism of melanoma progression will help to provide an insight into new future therapeutic approaches for melanoma.

Citing Articles

Nature's weapons: Bioactive compounds as anti-cancer agents.

Auti A, Tathode M, Marino M, Vitiello A, Ballini A, Miele F AIMS Public Health. 2024; 11(3):747-772.

PMID: 39416904 PMC: 11474324. DOI: 10.3934/publichealth.2024038.


Contribution of Keratinocytes in Skin Cancer Initiation and Progression.

Dainese-Marque O, Garcia V, Andrieu-Abadie N, Riond J Int J Mol Sci. 2024; 25(16).

PMID: 39201498 PMC: 11354502. DOI: 10.3390/ijms25168813.


The clinical relevance of OSM in inflammatory diseases: a comprehensive review.

Wolf C, Pruett C, Lighter D, Jorcyk C Front Immunol. 2023; 14:1239732.

PMID: 37841259 PMC: 10570509. DOI: 10.3389/fimmu.2023.1239732.


2-Methoxyestradiol-3,17-,-bis-sulfamate (STX140) Inhibits Proliferation and Invasion via Senescence Pathway Induction in Human BRAFi-Resistant Melanoma Cells.

Franco Y, de Moraes Jr M, Carvalho L, Dohle W, da Silva R, Noma I Int J Mol Sci. 2023; 24(14).

PMID: 37511073 PMC: 10378825. DOI: 10.3390/ijms241411314.


Phytochemicals as Immunomodulatory Agents in Melanoma.

Tabolacci C, De Vita D, Facchiano A, Bozzuto G, Beninati S, Failla C Int J Mol Sci. 2023; 24(3).

PMID: 36768978 PMC: 9916941. DOI: 10.3390/ijms24032657.